Views from the Field on Psychedelics in 2026: Excitement, Anxiety, and Open Questions

Psychedelics stakeholders look toward 2026 with tempered anticipation rather than guaranteed progress. The year is treated as pivotal, but responses emphasize sober realism about which breakthroughs, regulatory decisions, and patient access pathways may actually be clarified. Across the field, excitement is paired with specific forms of concern, particularly around uncertainty: what data will be decisive, what agencies will do, and how quickly access will expand in practice. Optimism exists, but it is constrained by recognition that key hurdles may persist even if momentum continues. The framing centers on open questions for 2026, using field input to map both hopes and anxieties, highlighting the gap between importance of the year and what it may concretely deliver.